Quest Laboratories (QUESTLAB) Stock Overview
Manufactures and sells pharmaceutical formulations in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
QUESTLAB Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Quest Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹112.00 |
| 52 Week High | ₹140.35 |
| 52 Week Low | ₹75.15 |
| Beta | 0 |
| 1 Month Change | -12.91% |
| 3 Month Change | 29.48% |
| 1 Year Change | 7.38% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -23.99% |
Recent News & Updates
Recent updates
Does Quest Laboratories (NSE:QUESTLAB) Have A Healthy Balance Sheet?
Feb 12
Concerns Surrounding Quest Laboratories' (NSE:QUESTLAB) Performance
Nov 21A Piece Of The Puzzle Missing From Quest Laboratories Limited's (NSE:QUESTLAB) 28% Share Price Climb
Jul 26Quest Laboratories' (NSE:QUESTLAB) Solid Profits Have Weak Fundamentals
Nov 22Not Many Are Piling Into Quest Laboratories Limited (NSE:QUESTLAB) Just Yet
Oct 22Shareholder Returns
| QUESTLAB | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.6% | -0.7% | -4.4% |
| 1Y | 7.4% | 7.1% | 4.9% |
Return vs Industry: QUESTLAB matched the Indian Pharmaceuticals industry which returned 7.1% over the past year.
Return vs Market: QUESTLAB exceeded the Indian Market which returned 4.9% over the past year.
Price Volatility
| QUESTLAB volatility | |
|---|---|
| QUESTLAB Average Weekly Movement | 10.4% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 3.9% |
Stable Share Price: QUESTLAB's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: QUESTLAB's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 50 | Anil Sabarwal | questlabltd.com |
Quest Laboratories Limited manufactures and sells pharmaceutical formulations in India. The company offers ethical drugs, generic drugs, and over the-counter drugs under various categories, such as antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and others. It provides its products in various forms, such as tablets, liquid orals, oral dry powders, oral powders, ointments, external liquids, and oral suspension.
Quest Laboratories Limited Fundamentals Summary
| QUESTLAB fundamental statistics | |
|---|---|
| Market cap | ₹1.84b |
| Earnings (TTM) | ₹213.89m |
| Revenue (TTM) | ₹1.26b |
Is QUESTLAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QUESTLAB income statement (TTM) | |
|---|---|
| Revenue | ₹1.26b |
| Cost of Revenue | ₹1.04b |
| Gross Profit | ₹219.67m |
| Other Expenses | ₹5.78m |
| Earnings | ₹213.89m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 13.05 |
| Gross Margin | 17.44% |
| Net Profit Margin | 16.99% |
| Debt/Equity Ratio | 36.5% |
How did QUESTLAB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/15 04:57 |
| End of Day Share Price | 2026/03/13 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Quest Laboratories Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.